Skip to main content


Table 1 Therapeutic agents for T2DM and their effect NAFLD/NASH in clinical trials

From: Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus

Treatment Mechanism of action AST/ALT Liver fat by imaging Liver histology
 Metformin [38,45-48] Insulin-sensitizer ↓*,↔^ Unchanged
 Pioglitazone [52, 53, 55] PPARγ agonist ↓^ Improved
 Sitagliptin [72, 80, 81] DPP-4 inhibitor n/a n/a
 Vildagliptin [82] DPP-4 inhibitor ↓^ n/a
 Canagliflozin [90] Inhibits renal glucose reabsortion n/a n/a
 Dapagliflozin [91, 92] Inhibits renal glucose reabsortion n/a n/a
 Exenatide [70] GLP-1 receptor agonist ↓^ n/a
 Liraglutide [69-75] GLP-1 receptor agonist ↓**,^ Improved
  1. *NAFLD assessed by ultrasound, **NAFLD assessed by CT, ^NAFLD assessed by MRI/1H-MRS, n/a: data not available